Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib and RAD-001 in HER2+ Metastatic Breast Cancer
NCT01283789Phase 2Unknown
- Sponsor
- University of Kansas Medical Center
- Start
- Feb 2011
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in HER2-positive metastatic breast cancer, sponsored by University of Kansas Medical Center. Primary endpoint: Effectiveness of the combination of RAD-001 and lapatinib at 6 months. Status: unknown.
02
Drugs
everolimus
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT01283789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01283789.